Science

Biotech firms are meant to pay to use Earth’s genetic data. They’re not.

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 03/11/2026, 18:35:28 UTC.

Briefings

A 2026 biodiversity summit reported that global leaders criticized biotech firms for using public genetic data without contributing to a voluntary nature protection fund. The article notes that companies are not legally required to pay for this data access, despite the environmental concerns raised by summit attendees.

Key points

• Global leaders at COP17 biodiversity summit complained that companies using public genetic data are not paying into a voluntary fund to protect nature.
• Biotech firms are not legally required to pay for the use of public genetic data, even when that data is used to support environmental conservation efforts.

Context

The article highlights a conflict between biotechnology industry practices and global biodiversity conservation goals, specifically regarding the use of genetic data in research and development.

Limitations

Evidence is limited to a single report from a biodiversity summit; specific details about the fund's mechanics, the number of companies involved, or the exact scope of the criticism are not provided.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 03/11/2026, 18:40:00 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeihttwcbrt5aqnlpkzub4jwqkhyir4sjkyyod2aelzyawkf7xjegqu